Stock Track | AKESO Soars 5.53% Intraday on Positive Phase III Quality-of-Life Results for Ivonescimab

Stock Track04-01

AKESO's stock price surged 5.53% during intraday trading on Wednesday, following the release of encouraging clinical data for its flagship oncology drug.

The company presented patient-reported outcomes from its Phase III HARMONi-2 study at the ELCC 2026 conference, showing that its drug ivonescimab improved overall well-being and daily functioning compared to Merck's Keytruda (pembrolizumab) in first-line PD-L1-positive non-small cell lung cancer. The data indicated better control of key lung cancer symptoms, including a sustained advantage in managing breathing-related complaints.

Akeso positioned these quality-of-life findings as supportive of broader uptake for ivonescimab, which has been marketed in China since 2025. The results build upon prior efficacy data from the same head-to-head study that showed ivonescimab outperforming Keytruda, strengthening the company's push to establish the therapy as a new standard of care in the competitive lung cancer treatment landscape.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124816078?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 11:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124816078","market":"us","top_or_hot":-1,"title":"Stock Track | AKESO Soars 5.53% Intraday on Positive Phase III Quality-of-Life Results for Ivonescimab","media":"Stock Track","content":"<p>AKESO's stock price surged 5.53% during intraday trading on Wednesday, following the release of encouraging clinical data for its flagship oncology drug.</p><p>The company presented patient-reported outcomes from its Phase III HARMONi-2 study at the ELCC 2026 conference, showing that its drug ivonescimab improved overall well-being and daily functioning compared to Merck's Keytruda (pembrolizumab) in first-line PD-L1-positive non-small cell lung cancer. The data indicated better control of key lung cancer symptoms, including a sustained advantage in managing breathing-related complaints.</p><p>Akeso positioned these quality-of-life findings as supportive of broader uptake for ivonescimab, which has been marketed in China since 2025. The results build upon prior efficacy data from the same head-to-head study that showed ivonescimab outperforming Keytruda, strengthening the company's push to establish the therapy as a new standard of care in the competitive lung cancer treatment landscape.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AKESO Soars 5.53% Intraday on Positive Phase III Quality-of-Life Results for Ivonescimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AKESO Soars 5.53% Intraday on Positive Phase III Quality-of-Life Results for Ivonescimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-01 11:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AKESO's stock price surged 5.53% during intraday trading on Wednesday, following the release of encouraging clinical data for its flagship oncology drug.</p><p>The company presented patient-reported outcomes from its Phase III HARMONi-2 study at the ELCC 2026 conference, showing that its drug ivonescimab improved overall well-being and daily functioning compared to Merck's Keytruda (pembrolizumab) in first-line PD-L1-positive non-small cell lung cancer. The data indicated better control of key lung cancer symptoms, including a sustained advantage in managing breathing-related complaints.</p><p>Akeso positioned these quality-of-life findings as supportive of broader uptake for ivonescimab, which has been marketed in China since 2025. The results build upon prior efficacy data from the same head-to-head study that showed ivonescimab outperforming Keytruda, strengthening the company's push to establish the therapy as a new standard of care in the competitive lung cancer treatment landscape.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1124816078","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124816078","pubTimestamp":1775014801,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AKESO's stock price surged 5.53% during intraday trading on Wednesday, following the release of encouraging clinical data for its flagship oncology drug.The company presented patient-reported...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"个股追踪|ivonescimab III期生活质量结果积极康方生物盘中大涨5.53%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"AKESO's stock price surged 5.53% during intraday trading on Wednesday, following the release of encouraging clinical data for its flagship oncology drug.The company presented patient-reported outcomes from its Phase III HARMONi-2 study at the ELCC 2026 conference, showing that its drug ivonescimab improved overall well-being and daily functioning compared to Merck's Keytruda (pembrolizumab) in first-line PD-L1-positive non-small cell lung cancer. The data indicated better control of key lung cancer symptoms, including a sustained advantage in managing breathing-related complaints.Akeso positioned these quality-of-life findings as supportive of broader uptake for ivonescimab, which has been marketed in China since 2025. The results build upon prior efficacy data from the same head-to-head study that showed ivonescimab outperforming Keytruda, strengthening the company's push to establish the therapy as a new standard of care in the competitive lung cancer treatment landscape.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124816078","isCrawlerRequest":true}